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Abstract
An 80-year-old man with no history of an immune-compromising disorder was diagnosed with progressive multi-
focal leukoencephalopathy (PML). He presented with dysphagia and left-sided weakness; magnetic resonance ima-
ging demonstrated marked signal abnormality in the subcortical white matter of the left frontal lobe and in the
posterior limb of the right internal capsule. Polymerase chain reaction (PCR) analysis of the cerebrospinal fluid (CSF)
was negative for John Cunningham (JC) virus. On brain biopsy, foamy macrophages infiltrating the white matter
were identified, staining positive for anti-simian virus 40 antibodies. Postoperatively, PCR for JC viral DNA in the CSF
was positive, establishing the diagnosis of PML. Extensive investigation for an occult immunocompromising disor-
der was negative. The patient’s neurologic deficits rapidly increased throughout his hospital stay, and he died
3.5 months after his diagnosis.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a
rapidly advancing demyelinating disorder of the central
nervous system almost exclusively encountered in immu-
nocompromised individuals[1]. It is caused by reactivation
of the John Cunningham virus (JCV) under conditions of
cellular immunocompromise such as those encountered in
patients with acquired immunodeficiency syndrome
(AIDS), patients with hematologic and solid organ malig-
nancies receiving chemotherapy, and transplant recipients
under immunosuppression[2]. The interest in this disease
has recently increased because of its association with nata-
lizumab, a monoclonal antibody directed against a4 integ-
rins that is used to treat Crohn’s disease[3] and multiple
sclerosis[4].
Here, we describe a rare occurrence of PML, with a
rapidly fatal outcome, in a patient without an apparent
history of immunosuppression.
Case Report
An 80-year-old white man with a medical history of hyper-
tension presented to the emergency department of an out-
side hospital after sustaining a fall. He had begun to drag
his left leg at least one month prior to presentation, and
over the preceding 5 days he had started to use a walker.
The left-sided weakness was accompanied by progressive
dysphagia, which occurred initially with fast eating and
later with a regular eating rate. He had lost 35 lbs over the
preceding 3 months. He had visited the emergency center
monthly in the preceding 3 months because of falls. The
patient was started on aspirin 25 mg/extended-release
dipyridamole (Aggrenox®) 200 mg PO daily for suspected
transient ischemic attacks.
At the time of presentation at Tyler County Hospital
on May 16, 2008, a computed tomography (CT) of the
patient’s head demonstrated multiple cerebrovascular
accidents. Cerebral atrophy and old infarcts in the right
internal capsule, right cerebral peduncle, right thalamus,
and left frontal lobe were identified. The patient was
transferred from Tyler County Hospital in Woodville,
Texas, to Christus St. Elizabeth Hospital in Beaumont,
Texas, for a higher level of care.
Upon physical examination by the physicians at Chris-
tus St. Elizabeth Hospital, the patient’s blood pressure
was 158/81 mmHg, his respiratory rate 12 breaths per
minute, heart rate 90 beats per minute, and temperature
37°Celsius. The patient was described as a cachectic
C a u c a s i a nm a n ,a l e r t ,a w a k e ,a n do r i e n t e dt op e r s o n ,
time, and place. His speech was fluent; comprehension,
naming, and repetition were intact. Examination of the
cranial nerves showed mild drooping of the left angle of
the mouth; all other cranial nerves were intact. Left
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left symmetrically in the upper and lower extremities
and 5-/5 in the right extremities. Deep tendon reflexes
were hyperactive, but no extensor plantar responses
were recorded. On admission to Christus St. Elizabeth
Hospital, complete blood count and chemistry levels
were normal, except for blood urea nitrogen and serum
creatinine levels of 37 mg/dL and 2.4 mg/dL, respec-
tively, indicating acute or chronic nephropathy. There
was no history of renal insufficiency.
On his second hospital day, a magnetic resonance ima-
ging (MRI) study of the brain without contrast demon-
strated ill-defined white matter edema involving the right
thalamus and left paramidline frontal lobe (sparing the
cortex) and extending into the right cerebral peduncle.
The lesions appeared bright on fluid-attenuated inversion
recovery (FLAIR) sequences and diffusion images.
The findings raised concern about an underlying
malignancy. Clinical findings and imaging studies (CT
of the chest/abdomen/pelvis) did not, however, demon-
strate any suspicious lesions. Immunofixation analysis
was negative for antineuronal nuclear antibodies type 1
(anti-Hu) and 2 (anti-Ri). Renal and transrectal ultraso-
nography were conducted on the third inpatient day,
prompted by the patient’s newly diagnosed renal insuffi-
ciency, without contributory findings. A spinal tap
yielded clear, colorless cerebrospinal fluid (CSF) with
the following component levels: glucose 55 mg/dL
(serum level, 88 mg/dL) and protein 31 mg/dL. Gram
staining and culture were negative. On cytospin prepara-
tions, 10 cells were collected: 70% normal lymphocytes
and 30% monocytes. A specimen was sent for polymer-
ase chain reaction (PCR) analysis for JC virus and
herpes simplex virus; both studies were negative. The
CSF was also negative for the presence of Borrelia burg-
dorferi antigens. Myelin basic protein was elevated
(12.63 ng/mL, reference < 4 ng/mL); no oligoclonal
bands were identified. An electroencephalogram demon-
strated mild bifrontal slowing, more prominent on the
left than the right. A carotid Doppler ultrasound was
normal. Serum and urine protein electrophoreses were
consistent with proteinuria of glomerular pattern but
negative for the presence of paraprotein.
On day 11, the patient experienced deterioration of his
neurologic symptoms. On neurologic examination, the
patient was awake but drowsy and oriented to time,
place, and person. Mild left facial nerve palsy was again
noted. Motor strength was 5/5 on the right, whereas on
the left there was progressive weakness; motor strength
was 2/5 on the left hand, 4-/5 on the left biceps, and 4-/
5 over the left leg. Deep tendon reflexes were 2+, and
no extensor plantar responses were reported. Coordina-
tion was normal on the right side, whereas some ataxia
was recorded on the left. MRI without contrast of the
cervical, thoracic, and lumbar spine on day 12 demon-
strated no major stenosis or neural impingement. MRI
of the brain on day 13 demonstrated two areas of
abnormal signals on diffusion-weighted imaging (left
frontal lobe measuring 2.7 × 2.7 cm and right thalamus
and basal ganglion measuring 1.6 × 1.2 cm). FLAIR
images were positive in these areas and in several other
small areas elsewhere. No significant change was identi-
fied when this study was compared with the one
obtained on the second inpatient day.
A brain biopsy was considered, and the patient was
transferred to Memorial Hermann Hospital, Houston,
Texas, on June 6, 2008. On admission, his vital signs
were within normal limits. He was described as a
cachectic Caucasian man with a poor performance sta-
tus. His neurologic examination was remarkable for left
facial drooping and left-sided weakness (1/5 in the left
upper and 2/5 in the left lower extremity). Deep tendon
reflexes were hyperactive on the left side and normal on
the right side. In addition, pinprick, hot and cold, light
touch, and vibratory sensation and proprioception were
decreased on the left side. Gait could not be assessed
due to his left motor weakness. His Folstein Mini Men-
tal State Examination score was 23/30; orientation was
intact, whereas registration (1/3) and recollection (0/3)
were severely affected.
A repeat MRI at Memorial Hermann Hospital showed
two prominent areas of signal abnormality: one in the
subcortical white matter of the left frontal lobe and one
in the right posterior limb of the internal capsule and
thalamus extending along the corticospinal tract as far
d o w na st h ep o n s .T h el e s i o n sw e r eh y p o i n t e n s eo n
T1-weighted images and hyperintense on T2-weighted
images. The cortex was spared (figure 1).
Twenty-five days after his initial presentation, the
patient underwent image-guided open brain biopsy
through a left frontal craniotomy. Hematoxylin and
eosin staining of the biopsy tissue revealed foamy
macrophages infiltrating the brain tissue. Reactive gliosis
with bizarre astrocytes was also seen. Stains for herpes
simplex virus, cytomegalovirus, adenovirus, and Toxo-
plasma gondii were negative. Immunohistochemical
staining with anti-simian virus 40 antibody was positive.
T h el a t t e ra n t i b o d ys t a i n sp o s i t i v ef o rh u m a np o l y o m a -
viruses (JC virus, BK virus; KI polyomavirus, WU polyo-
mavirus, and Merkel cell polyomavirus[5]) (figure 2).
PCR of the CSF for JCV conducted in the same labora-
tory as previously was positive, establishing the diagno-
sis. The sensitivity level of the PCR was not available in
the report but generally the sensitivity is 10
-3 to 10
-4.
This unexpected finding spawned a thorough investi-
gation for an occult immunocompromising disorder.
Testing for the human immunodeficiency virus (HIV)
w a sn e g a t i v eb ye n z y m ei m m u n o a s s a y( t w i c e )a n dP C R .
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Page 2 of 5Figure 1 Imaging studies conducted in the final hospital. A, computed tomography of the head without contrast. B, T1-weighted magnetic
resonance imaging of the head. C and D, T2-weighted magnetic resonance imaging of the head. The arrows indicate the subcortical lesion in
the left frontal lobe; the block arrows indicate the lesion in the right posterior limb of the internal capsule and thalamus extending along the
corticospinal tract (solid arrow, image D)
Figure 2 Biopsy specimen of the brain lesion. A, infiltrating foamy macrophages (arrows) and reactive astrocytes (block arrows) on
hematoxylin and eosin stain of a deep white matter biopsy. B, positive stain for simian virus 40 (stains polyomavirus in humans).
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Page 3 of 5The patient’s CD4 count was 332 cells/μl (normal range,
410-1590 cells/μl) and his CD8 count was 485 cells/μl
(normal range, 190-1140 cells/μl), as measured by flow
cytometry. Testing for other infectious causes (toxoplas-
mosis, hepatitides, Cryptococcus, human T-lymphotropic
virus I and II) was also negative. His persistent lympho-
penia (absolute lymphocyte count throughout the hospi-
tal course ranged between 120 and 1077 cells/μl) raised
the suspicion for a rheumatologic disease. Athough his
antinuclear antibody titer was high (1:1280), he did not
meet any clinical criteria for lupus erythematosus. Test-
ing for anti-Ro and anti-La autoantibodies was positive,
but the absence of xerostomia/xerophthalmia and a
negative biopsy of minor salivary glands did not sub-
stantiate the diagnosis of Sjögren syndrome. The rest of
the rheumatologic testing (anti-double-stranded DNA,
cyclic citrullinated peptide, anti-smooth muscle and
anti-RNP antibodies; rapid plasma reagin; complement 3
and 4 levels) was unrevealing. A bone marrow biopsy
revealed variable cellularity (10-30%), with trilineage
hematopoiesis and increased iron stores. There was no
morphologic evidence of malignancy. Stains and cultures
for acid-fast bacilli and fungi and cultures for cytomega-
lovirus were negative. The chromosomal analysis was
negative as well.
Throughout the rest of his hospital stay, the patient’s
neurologic condition continued to deteriorate. His
course was marked by an episode of altered mental
status, progressive dementia, motor weakness, declining
visual acuity, and worsening performance status. He was
discharged to a skilled nursing facility closer to home,
where he died 3.5 months after the diagnosis of PML.
Discussion
Progressive multifocal leukoencephalopathy was originally
described in 1958 in two patients with chronic lymphocy-
tic leukemia and one patient with Hodgkin’s disease[6].
The causative agent, the JC virus, was isolated in 1971
from the brain of a patient with Hodgkin’s disease, and the
virus was named after him[7]. With the advent of the HIV
epidemic, PML was recognized as a major opportunistic
infection of AIDS,[8] but with effective antiretroviral ther-
apy, its incidence and attributable mortality rates have
decreased[9]. Most recently, interest in PML has been
revived by its association with natalizumab (Tysabri®), a
promising new drug for the treatment of multiple sclerosis
and Crohn’s disease[2].
The occurrence of PML in persons without known
immunosuppression is exceedingly rare. Although tra-
ditionally associated with conditions of cellular immu-
nocompromise, the concept that profound cellular
immunosuppression is required for the reactivation of
the JC virus has recently been challenged [10].
Although old age has been associated with idiopathic
CD4+ lymphocytopenia,[11] and the latter has been
associated with PML,[10,12] our patient did not meet
the Centers for Disease Control and Prevention criteria
for idiopathic CD4+ lymphocytopenia [13]. With his
lymphocyte count ranging between 120 and 1077
lymphocytes per microliter, however, it is possible that
he had transient CD4+ lymphocytopenia. The associa-
tion of aging with CD4+ lymphocytopenia[11] and the
high JCV seroprevalence in adults[14] should increase
awareness about the possible diagnosis of PML in the
appropriate clinical and radiographic setting.
The initially negative PCR results for JC virus in the
CSF, despite the suspicious radiologic findings, delayed
the diagnosis. Negative PCR results for JCV-DNA in the
CSF have been described in patients with AIDS,[15] and
a correlation with active antiretroviral treatment has
been hypothesized[1]. CSF obtained after open brain
biopsy was positive for JCV-DNA, indicating that a
breach in the blood-brain barrier or progressive infec-
tion may have led to the dissemination of the virus in
the subarachnoid space. The fact that a negative PCR
result for JCV-DNA cannot completely exclude PML
has raised the need for a new consensus terminology, in
which immunosuppressed patients with clinical and
radiographic features consistent with PML and no alter-
native etiology should be considered as “possible
PML”[1].
The occurrence of PML in patients without identifiable
immunodeficiency poses a challenge from a therapeutic
perspective. While strategies to reverse immunodefi-
ciency, such as discontinuation of immunosuppressive
therapy, institution of antiretroviral therapy in HIV-posi-
tive patients[1], plasma exchange and immunoadsorption
in natalizumab treated patients [16], work well in certain
groups, no treatment options of proven efficacy exist for
patients without a clear immune disorder[17]. Cytarabine
[18], cidofovir[19], topotecan[20], and mirtazapine[21]
have been investigated as therapeutic agents, mostly in
patients with AIDS, with variable results and toxicities.
A study to investigate the effects of mefloquine in PML is
currently ongoing[22].
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